Andrew S. Protheroe
Impact in
- Pulmonary and Respiratory Medicine top 0.2%
- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
- Renal cell carcinoma treatment
- Cancer Research top 1%
- Cancer, Lipids, and Metabolism
Papers in
-
- Renal cell carcinoma treatment 28
- Prostate Cancer Treatment and Research 25
- Oncology 29
- Cancer Immunotherapy and Biomarkers 11
- Co-authors
- Karim S. Fizazi (8 shared papers)Alfredo Rodríguez-Antolín (6 shared papers)Nobuaki Matsubara (7 shared papers)Kim N. Chi (4 shared papers)Mustafa Özgüroğlu (4 shared papers)Luis Enrique Fein (4 shared papers)Susan Feyerabend (4 shared papers)B. Yа. Alekseev (4 shared papers)
- Journals
- Annals of Oncology (10 papers)British Journal of Cancer (9 papers)The Lancet Oncology (8 papers)British Journal of Urology (6 papers)European Journal of Cancer (5 papers)
- Partner nations
- United KingdomUnited StatesFrance
In The Last Decade
Andrew S. Protheroe
122 papers receiving 11.6k citations
Andrew S. Protheroe's Hit Papers
Peers
Comparison fields: 5 of 141
- Pulmonary and Respiratory Medicine 6.1k
- Cancer Research 1.9k
- Oncology 2.5k
- Endocrinology, Diabetes and Metabolism 861
- Radiology, Nuclear Medicine and Imaging 1.1k
Countries citing papers authored by Andrew S. Protheroe
This map shows the geographic impact of Andrew S. Protheroe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew S. Protheroe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew S. Protheroe more than expected).
Fields of papers citing papers by Andrew S. Protheroe
This network shows the impact of papers produced by Andrew S. Protheroe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew S. Protheroe. The network helps show where Andrew S. Protheroe may publish in the future.
Co-authors
The 25 scholars most cited alongside Andrew S. Protheroe, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 129 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer Hit paper breakdown → | 2015 | 1813 |
| 2 | Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer Hit paper breakdown → | 2017 | 1714 |
| 3 | Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy Hit paper breakdown → | 2017 | 1350 |
| 4 | Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial Hit paper breakdown → | 2019 | 618 |
| 5 | 2005 | 500 | |
| 6 | Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial Hit paper breakdown → | 2019 | 457 |
| 7 | 2008 | 379 | |
| 8 | Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial Hit paper breakdown → | 2016 | 358 |
| 9 | Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial Hit paper breakdown → | 2019 | 313 |
| 10 | 2014 | 249 | |
| 11 | 2018 | 196 | |
| 12 | 2010 | 177 | |
| 13 | 2014 | 168 | |
| 14 | 2021 | 165 | |
| 15 | Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder Hit paper breakdown → | 2022 | 157 |
| 16 | 2018 | 136 | |
| 17 | 2010 | 120 | |
| 18 | 2019 | 101 | |
| 19 | 2012 | 96 | |
| 20 | 2015 | 95 |
About Andrew S. Protheroe
Andrew S. Protheroe is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Surgery, Cancer Research and Hematology, having authored 129 papers that have together received 11.8k indexed citations. Recurring topics across this work include Renal cell carcinoma treatment (28 papers), Prostate Cancer Treatment and Research (25 papers), Bladder and Urothelial Cancer Treatments (17 papers), Testicular diseases and treatments (15 papers), Cancer Immunotherapy and Biomarkers (11 papers), Renal and related cancers (10 papers), Cancer Genomics and Diagnostics (9 papers) and Urinary and Genital Oncology Studies (8 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (6.1k citations), Cancer Research (1.9k citations), Oncology (2.5k citations), Endocrinology, Diabetes and Metabolism (861 citations) and Radiology, Nuclear Medicine and Imaging (1.1k citations). Andrew S. Protheroe has collaborated with scholars based in United Kingdom, United States and France. Frequent co-authors include Karim S. Fizazi, Alfredo Rodríguez-Antolín, Nobuaki Matsubara, Kim N. Chi, Mustafa Özgüroğlu, Luis Enrique Fein, Susan Feyerabend, B. Yа. Alekseev, Dingwei Ye and Valentine M. Macaulay. Their work appears in journals such as Annals of Oncology, British Journal of Cancer, The Lancet Oncology, British Journal of Urology and European Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.